A high-throughput fluorimetric assay for 2-Hydroxyglutarate Identifies Zaprinast as a Glutaminase Inhibitor

Cancer Discovery

Volumn 4, Issue 7, 2014, Pages 828-839

  Elhammali, Adnan ^a   Ippolito, Joseph E ^a   Collins, Lynne ^a   Crowley, Jan ^b   Marasa, Jayne ^a   Piwnica Worms, David ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; AGAR; CYCLIC GMP; ENZYME INHIBITOR; GLUTAMINASE; GLUTAMINASE INHIBITOR; HISTONE; ISOCITRATE DEHYDROGENASE 1; REACTIVE OXYGEN METABOLITE; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; ZAPRINAST; ALPHA-HYDROXYGLUTARATE; GLUTARIC ACID DERIVATIVE; ISOCITRATE DEHYDROGENASE; PURINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL MUTANT; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUOROMETRY; GENE MUTATION; GENETIC TRANSFECTION; HIGH THROUGHPUT SCREENING; HISTONE METHYLATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIMIT OF QUANTITATION; MASS FRAGMENTOGRAPHY; MOUSE; NEOPLASM; NONHUMAN; PANCREATIC CANCER CELL LINE; PLASMID; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; FIBROSARCOMA; HEK293 CELL LINE; METABOLISM; METHYLATION; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; ENZYME INHIBITORS; FIBROSARCOMA; GLUTAMINASE; GLUTARATES; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HISTONES; HUMANS; ISOCITRATE DEHYDROGENASE; METHYLATION; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PURINONES;

EID: 84904042360     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0572     Document Type: Article

References (34)

1. DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010; 29: 313-24.
2. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A 2008; 105: 18782-7.
3. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009; 458: 762-5.
4. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, et al. Glutamine supports pancreatic cancer growth through a KRASregulated metabolic pathway. Nature 2013; 496: 101-5.
5. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-44.
6. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-12.
7. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-73.
8. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058-66.
9. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 2011; 224: 334-43.
10. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012; 17: 72-9.
11. Losman JA, Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 2013; 27: 836-52.
12. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutaratedependent dioxygenases. Cancer Cell 2011; 19: 17-30.
13. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553-67.
14. Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012; 483: 484-8.
15. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012; 483: 474-8.
16. Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013; 339: 1621-5.
17. Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brustle A, et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012; 488: 656-9.
18. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013; 340: 626-30.
19. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013; 340: 622-6.
20. Zhao G, Winkler ME. A novel alpha-ketoglutarate reductase activity of the serA-encoded 3-phosphoglycerate dehydrogenase of Escherichia coli K-12 and its possible implications for human 2-hydroxyglutaric aciduria. J Bacteriol 1996; 178: 232-9.
21. Zhu A, Romero R, Petty HR. An enzymatic fluorimetric assay for glucose-6-phosphate: application in an in vitro Warburg-like effect. Anal Biochem 2009; 388: 97-101.
22. Sandner P, Hutter J, Tinel H, Ziegelbauer K, Bischoff E. PDE5 inhibitors beyond erectile dysfunction. Int J Impot Res 2007; 19: 533-43.
23. Martin E, Sharina I, Kots A, Murad F. A constitutively activated mutant of human soluble guanylyl cyclase (sGC): implication for the mechanism of sGC activation. Proc Natl Acad Sci U S A 2003; 100: 9208-13.
24. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 2007; 104: 19345-50.
25. Balss J, Pusch S, Beck AC, Herold-Mende C, Kramer A, Thiede C, et al. Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate. Acta Neuropathol 2012; 124: 883-91.
26. Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov 2012; 11: 937-57.
27. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 2010; 70: 8981-7.
28. Cheng T, Sudderth J, Yang C, Mullen AR, Jin ES, Mates JM, et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci U S A 2011; 108: 8674-9.
29. Cassago A, Ferreira AP, Ferreira IM, Fornezari C, Gomes ER, Greene KS, et al. Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism. Proc Natl Acad Sci U S A 2012; 109: 1092-7.
30. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010; 18: 207-19.
31. Shukla K, Ferraris DV, Thomas AG, Stathis M, Duvall B, Delahanty G, et al. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem 2012; 55: 10551-63.
32. Grant GA, Xu XL, Hu Z. The relationship between effector binding and inhibition of activity in D-3-phosphoglycerate dehydrogenase. Protein Sci 1999; 8: 2501-5.
33. Naik S, Dothager RS, Marasa J, Lewis CL, Piwnica-Worms D. Vascular endothelial growth factor receptor-1 is synthetic lethal to aberrant {beta}-catenin activation in colon cancer. Clin Cancer Res 2009; 15: 7529-37.
34. Kenny J, Bao Y, Hamm B, Taylor L, Toth A, Wagers B, et al. Bacterial expression, purification, and characterization of rat kidney-type mitochondrial glutaminase. Protein Expr Purif 2003; 31: 140-8.